IRIS
FERRARA, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.416
EU - Europa 2.104
NA - Nord America 1.289
SA - Sud America 297
AF - Africa 33
AN - Antartide 1
OC - Oceania 1
Totale 7.141
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 2.055
RU - Federazione Russa 1.253
US - Stati Uniti d'America 1.183
CN - Cina 536
HK - Hong Kong 367
RO - Romania 266
BR - Brasile 249
IT - Italia 246
VN - Vietnam 167
BD - Bangladesh 149
FR - Francia 96
GB - Regno Unito 55
CA - Canada 47
MX - Messico 42
DE - Germania 41
NL - Olanda 27
IN - India 26
AR - Argentina 20
TR - Turchia 20
PL - Polonia 19
AT - Austria 17
SE - Svezia 17
ZA - Sudafrica 17
ES - Italia 15
FI - Finlandia 13
LT - Lituania 12
UA - Ucraina 11
ID - Indonesia 10
IQ - Iraq 10
JP - Giappone 9
PK - Pakistan 8
SA - Arabia Saudita 8
EC - Ecuador 7
AE - Emirati Arabi Uniti 6
CO - Colombia 6
JM - Giamaica 6
MY - Malesia 6
IE - Irlanda 4
KZ - Kazakistan 4
MA - Marocco 4
NP - Nepal 4
UZ - Uzbekistan 4
VE - Venezuela 4
AZ - Azerbaigian 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
ET - Etiopia 3
IL - Israele 3
JO - Giordania 3
NI - Nicaragua 3
PH - Filippine 3
TH - Thailandia 3
UY - Uruguay 3
BH - Bahrain 2
BO - Bolivia 2
CH - Svizzera 2
CR - Costa Rica 2
GT - Guatemala 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
PY - Paraguay 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BJ - Benin 1
CI - Costa d'Avorio 1
CL - Cile 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EG - Egitto 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
KE - Kenya 1
KH - Cambogia 1
KR - Corea 1
LV - Lettonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
RS - Serbia 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
Totale 7.141
Salva come PNG Salva come JPEG
Città #
Hong Kong 364
Singapore 297
San Jose 285
Moscow 268
Ashburn 173
Beijing 150
Dallas 132
Hefei 96
New York 85
Lauterbourg 80
Ho Chi Minh City 59
Los Angeles 48
Milan 42
Rome 33
Santa Clara 33
Hanoi 27
Mexico City 25
São Paulo 24
Denver 20
Orem 19
Montreal 15
Warsaw 14
Munich 13
Pasadena 13
Brooklyn 12
Buffalo 12
Florence 12
Houston 12
Manchester 12
Toronto 12
Vienna 12
Da Nang 11
Shanghai 11
Stockholm 11
Council Bluffs 10
Johannesburg 10
Rio de Janeiro 10
Ankara 9
Cesano Boscone 9
Haiphong 9
Phoenix 9
Poplar 9
Boardman 8
Boston 8
Chennai 8
Falkenstein 8
Helsinki 8
Naples 8
Amsterdam 7
Chicago 7
Nuremberg 7
Tianjin 7
Assago 6
Brasília 6
Frankfurt am Main 6
Kyiv 6
Seattle 6
Tokyo 6
Guangzhou 5
Istanbul 5
London 5
Porto Alegre 5
Querétaro 5
Riyadh 5
Rotherham 5
Adams Center 4
Baghdad 4
Barnet 4
Calgary 4
Campinas 4
Can Tho 4
Changsha 4
City of London 4
Dhaka 4
Goiânia 4
Hangzhou 4
Iesi 4
Kuala Lumpur 4
Las Vegas 4
Miami 4
Milwaukee 4
Parma 4
Shenzhen 4
Tashkent 4
Aalsmeer 3
Atlanta 3
Baie-D'Urfé 3
Baku 3
Bari 3
Bauru 3
Blumenau 3
Bogotá 3
Catania 3
Fortaleza 3
Guarulhos 3
Guayaquil 3
Ha Long 3
Harbin 3
Kathmandu 3
Kingston 3
Totale 2.778
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 388
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 230
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI) 194
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system 191
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 189
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer 187
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake 187
OncoAlert Round Table Discussions: The Global COVID-19 Experience 181
Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy 166
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors 160
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 120
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 116
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC 108
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 104
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 98
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 98
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle? 94
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 89
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program 86
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression 85
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer 85
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation 84
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171) 84
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer 82
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC 79
Myeloid cell heterogeneity in lung cancer: implication for immunotherapy 79
Hyperprogressive disease: recognizing a novel pattern to improve patient management 79
Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study 77
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 77
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study 76
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy 75
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers 74
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer 72
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 71
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Letter 69
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer 68
Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer 68
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 66
A Case of William's Syndrome in a Ugandan Child: A Feasible Diagnosis Even in a Low-Resource Setting 65
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 64
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction? 64
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer 63
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out 63
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy 61
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation 61
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy 61
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria 60
Atypical patterns of response and progression in the era of immunotherapy combinations 60
SMO mutations confer poor prognosis in malignant pleural mesothelioma 60
Immunotherapy 59
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort 58
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors 57
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors 56
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 55
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC 54
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers 54
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer 54
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective 54
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors 54
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer 52
Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events 52
Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments 51
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer 50
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy 50
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients 49
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 48
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer 47
Wide and Cystic Brain Metastases Reveal RET-Rearranged Non-Small-Cell Lung Cancers 46
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy 46
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy 46
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma 46
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis 46
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? 45
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 44
Unexpected Huge Prevalence of Intracardiac Extension of Wilms Tumor—A Single Center Experience from a Ugandan Hospital 43
The development of PARP as a successful target for cancer therapy 43
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors 43
Do immune checkpoint inhibitors need new studies methodology? 43
The Anti–Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers 43
Progress in the Management of Advanced Thoracic Malignancies in 2017 42
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 41
Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases 40
Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply 40
Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean? 40
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 40
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? 40
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 39
How to recognize and manage hyper-progression and pseudo-progression during immune checkpoint blockade in non-small cell lung cancer 39
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations 37
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients 37
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter? 36
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy-Reply 34
Is hyperprogressive disease a specific phenomenom of immunotherapy? 32
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial 31
Robotic Surgery Is a Safe Treatment in Very Elderly Patients with Resectable Lung Cancer 29
Multidisciplinary management of N2 stage III non-small cell lung cancer: opportunities and challenges for radiation oncology 23
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis 19
A viable human lung cancer tissue collection (LCTC) to accelerate translational research 7
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 5
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines 4
Totale 7.261
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.831
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.831
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222 0 0 2 0 0 0 0 0 0 0 0 0
2022/202314 3 2 1 0 0 1 1 2 0 0 2 2
2023/202440 2 4 2 2 2 5 6 3 3 3 1 7
2024/20252.532 16 6 1 6 9 7 404 66 214 300 761 742
2025/20264.691 383 308 146 440 413 170 417 321 1.282 300 251 260
Totale 7.279